Therapeutic Solutions International, Inc. (OTCPK: TSOI)
Health Care · Pharmaceuticals · US
$0.00
-99.00% today · -99.0% 1Y
Therapeutic Solutions International, Inc. (OTCPK: TSOI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $7.05K and employs 3 people.
Over the last twelve months the share price has lost 99.0%, trading between 0.00 and 0.00.
Tweenvest scores Therapeutic Solutions International, Inc. across four factors: quality 15/100, value 48/100, growth 100/100. Its strongest factor is growth.
TSOI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $7.05K
- Revenue (TTM)
- $85.32K
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- 0.22
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 7.05B
- Employees
- 3
- Next earnings
- —
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International, Inc. is dedicated to modulating the immune system to address a diverse array of serious conditions. The company formulates immune-modulatory agents targeting cancers, schizophrenia, suicidal ideation, and various neurological disorders like traumatic brain injury and chronic traumatic encephalopathy, alongside lung pathologies and general health maintenance. Its premier product, QuadraMune, is a patented, synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone, engineered to amplify natural killer cell activity and foster healthy cytokine production. In addition to QuadraMune, the company provides a range of nutraceuticals. These include ProJuvenol, an anti-aging capsule blend; various pterostilbene formulations like NanoStilbene (a nanoemulsion), DermalStilbene (a topical spray), IsoStilbene (an injectable form), and NeuroStilbene (an intranasal version); Nano Cannabidiol, a nanoparticle cannabidiol, and its composite NanoPlus (with NanoStilbene); as well as specialized blends such as NanoPSA (combining NanoStilbene and broccoli sprout extract) and the NLRP3 Trifecta (a two-product system with NanoPSA and GTE-50 green tea extract). Furthermore, the company is actively developing advanced therapeutics for chronic traumatic encephalopathy, traumatic brain injury, and lung diseases. Founded in 2007, Therapeutic Solutions International, Inc. is headquartered in Elk City, Idaho.
- ISIN
- US8833781011
- Founded
- 2007
- Listed since
- Jun 24, 2008
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.